Area of research
Epidemiology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Respiratory viral infections research, Pneumonia and Respiratory Infections, Chronic Obstructive Pulmonary Disease (COPD) Research, and Pediatric health and respiratory diseases.
Blood eosinopenia (≤30/µL) as an early predictor of respiratory failure in community-acquired pneumonia: A prospective multicentre study
TETRIS – Prospective study to observe clinical outcomes of triple therapy in COPD patients: Up to 12 months interim analysis
Community-acquired pneumonia in diabetic patients is characterised by a distinct pathogen spectrum and enhanced inflammation: results from CAPNETZ, a prospective observational cohort study.
Surface proteome of plasma extracellular vesicles differentiates between SARS-CoV-2 and influenza infection.
Publisher's note for Schierwagen et al., volume 325, 2023, p. C129-C140.
Advancing pleural effusion diagnosis: Application of Molecular Culture ID in pathogen detection.
Successful Mediastinal Cryobiopsy Using the Slim UCP190F EBUS Bronchoscope and a 25G Needle: Demonstrating the Efficacy of the Ariza-Pallares Approach.
Pre-diagnosed sleep apnoea is linked to severe courses in community-acquired pneumonia.
[From vibration trauma to disturbed sensorimotor function: The beginning of a vicious circle in obstructive sleep apnea (OSA)?]
Tumour Localisation With ICG-Soaked Embolisation Coils Without Robotic Bronchoscopy: First German Experience.
Blood eosinopenia (≤30/µL) as an early predictor of respiratory failure in community-acquired pneumonia: A prospective multicentre study.
Self-organising map clustering identifies high-risk clusters of post-acute mortality in a prospective multicentre study of community-acquired pneumonia.
Serotype distribution and coverage by pneumococcal vaccines in hospitalised adults with pneumococcal pneumonia in Germany.
Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform.
Epidemiology, risk factors, and clinical outcome of community-acquired pneumonia in severely immunosuppressed patients: a comprehensive analysis from the multinational prospective
<i>CAPNETZ Cohort</i>
Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform.
Burden of Respiratory Syncytial Virus Disease in Adults with Asthma and Chronic Obstructive Pulmonary Disease: A Systematic Literature Review.
Comparing viral, bacterial, and coinfections in community-acquired pneumonia, a retrospective cohort study
Update der S3-Leitlinie: Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie
[Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia].
A survey of diagnosis and therapy of inborn errors of immunity among practice-based physicians and clinic-based pneumologists and hemato-oncologists
Tumour Seeding After Transbronchial Cryobiopsy in a Patient With Newly Diagnosed Lung Cancer.
Proteomic, metabolomic and lipidomic profiles in community acquired pneumonia for differentiating viral and bacterial infections.
Predictors of high-flow nasal cannula (HFNC) failure in severe community-acquired pneumonia or COVID-19.
Design and rationale of MYOFLAME-19 randomised controlled trial: MYOcardial protection to reduce post-COVID inFLAMmatory heart disease using cardiovascular magnetic resonance Endpoints.
Community-acquired pneumonia in diabetic patients is characterised by a distinct pathogen spectrum and enhanced inflammation: results from CAPNETZ, a prospective observational cohort study
Older adults' and physicians' preferences for respiratory syncytial virus vaccination in Germany and Italy: A discrete choice experiment.
Retrospective cohort study of adult patients with cystic fibrosis supported with venovenous extracorporeal membrane oxygenation (VV ECMO) at a large German cystic fibrosis center.
Durability of the BNT162b2 XBB.1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform
Estimated Incidence Rate of Specific Types of Cardiovascular and Respiratory Hospitalizations Attributable to Respiratory Syncytial Virus Among Adults in Germany Between 2015 and 2019.